sens News

The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing shareholders. The resulting low tradable float also helped to prop up performance, and IPOs averaged a return of 25%, even...read more

Of the three scheduled healthcare offerings this past week, only two priced. This marks a total of seven IPOs year to date, all from healthcare companies, which have been predominantly development stage biotechs supported by existing backers. While the broader market is stabilizing and returns on recent IPOs are improving, investors are still awaiting the launch of IPOs by...read more

Senseonics Holdings, which is developing a long-lasting implantable glucose monitor for diabetics, raised $45 million by offering 15.8 million shares at $2.85. Senseonics Holdings plans to list on the NYSE MKT under the symbol SENS. Leerink Partners and Canaccord Genuity acted as lead managers on the deal....read more

Senseonics Holdings, which is developing a long-lasting implantable glucose monitor for diabetics, lowered the proposed deal size for its upcoming IPO on Thursday. The Germantown, MD-based company now plans to raise $45 million by offering 15.8 million shares at a price of $2.85. Insiders intend to purchase $17 million worth of shares in the offering. The company had previously...read more